Intellia Therapeutics reported it identified a genetic risk factor linked to liver enzyme elevations observed in patients receiving its CRISPR gene-editing treatment for ATTR amyloidosis. The company said the finding emerged from analysis of patients who experienced the highest liver laboratory elevations after dosing. The disclosure is notable for CRISPR programs that rely on in vivo nuclease delivery, where monitoring and managing hepatic signals are a recurring concern. Intellia’s update suggests the company can potentially stratify risk or inform monitoring protocols for future dosing decisions. As gene editing shifts toward broader commercialization, sponsor-level identification of correlating patient factors is increasingly likely to shape regulatory discussions, label language, and post-dosing management plans.